K S Kolibaba - JoVE Visualize

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Blood|October 26, 2000

Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cellsJ T Thiesing, S Ohno-Jones, K S Kolibaba, et al.

Leukemia & Lymphoma|April 8, 1999

CRKL binding to BCR-ABL and BCR-ABL transformationK S Kolibaba, A Bhat, C Heaney, et al.

FEBS Letters|November 24, 2004

Catalytic domains of tyrosine kinases determine the phosphorylation sites within c-CblA H Grossmann, K S Kolibaba, S G Willis, et al.

Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Blood|October 26, 2000

Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cellsJ T Thiesing, S Ohno-Jones, K S Kolibaba, et al.

Leukemia & Lymphoma|April 8, 1999

CRKL binding to BCR-ABL and BCR-ABL transformationK S Kolibaba, A Bhat, C Heaney, et al.

FEBS Letters|November 24, 2004

Catalytic domains of tyrosine kinases determine the phosphorylation sites within c-CblA H Grossmann, K S Kolibaba, S G Willis, et al.

Pageof 1